Background: BSR guidelines for management of Polymyalgia rheumatic (PMR) was published in 2010 which aimed to provide guidance for the diagnosis, management and monitoring of disease. A national audit on PMR was conducted across multiple rheumatology units across UK in order to assess the compliance to BSR guidelines. Methods: This study included retrospective analysis of patient records with a diagnosis of PMR more than 3 months on or after 1 July 2011. Patient information was collected through an online questionnaire from multiple centres across UK. The results were analysed by the Clinical audit team in University hospitals of Leicester NHS Trust. Results: We included 71 responses across 10 rheumatology units in UK. All PMR patients were more than 50 years and 56 (79%) were more than 60 years. It showed female predominance 47(67%). Most of our patients met the BSR criterion for diagnosis of PMR such as new onset pain (96.5%), duration more than 2 weeks (93%), bilateral shoulder or pelvic girdle aching (98%), morning stiffness more than 45 minutes (79%) and evidence of acute phase response (83%). Although more than 97% of patients underwent routine investigations including bone profile and inflammatory makers, there were poor compliance to guidelines in terms of immunological screen such as protein electrophoresis (55%), BJ proteins (27%), RF(56%), ACCP(50%),ANA(35%) and radiological investigations including chest X-ray (57%). Only (12%) received US scan of shoulders. There were wide differences in the treatment of PMR. Only 52(74%) of patients received initial management according to BSR guidelines. Rheumatologists did not prefer parenteral steroid injection as an initial management. Oral prednisolone dose reduction was compliant only in 29(41%) of patients. Although bone protection was considered in 64(90%) of patients, only 59(84%) followed the guidelines. Follow up of PMR patients were poorly compliant (43%). 33(47%) of patients experienced relapse, mostly within first 12 months. It highlighted wide variation in treatment of relapses e.g. incremental dose of prednisolone 31(45%) and DMARDs 11(16%). Patient education was provided with 68(96%) of our patients and 66(93%) received counselling from medical profession. Conclusion: We observed a wide variation in clinical practice in UK and it highlighted poor compliance to BSR guidelines in terms of diagnosis (64.3%), initiation (74%) and reduction (41%) of prednisolone dosage and follow-up of patients (43%). This reflects poor embedment of BSR guidelines among health professionals despite being in existence for last 3 years. Possible causes could be lack of awareness about existing guidelines, involvement of various disciplines (other than rheumatology) in management of PMR patients. We aspire to better adherence and implementation of national guidance across various specialities in order to provide best practice.
Background: BSR guidelines for management of Polymyalgia rheumatic (PMR) was published in 2010 which aimed to provide guidance for the diagnosis, management and monitoring of disease. A national audit on PMR was conducted across multiple rheumatology units across UK in order to assess the compliance to BSR guidelines. Methods: This study included retrospective analysis of patient records with a diagnosis of PMR more than 3 months on or after 1 July 2011. Patient information was collected through an online questionnaire from multiple centres across UK. The results were analysed by the Clinical audit team in University hospitals of Leicester NHS Trust. Results: We included 71 responses across 10 rheumatology units in UK. All PMR patients were more than 50 years and 56 (79%) were more than 60 years. It showed female predominance 47(67%). Most of our patients met the BSR criterion for diagnosis of PMR such as new onset pain (96.5%), duration more than 2 weeks (93%), bilateral shoulder or pelvic girdle aching (98%), morning stiffness more than 45 minutes (79%) and evidence of acute phase response (83%). Although more than 97% of patients underwent routine investigations including bone profile and inflammatory makers, there were poor compliance to guidelines in terms of immunological screen such as protein electrophoresis (55%), BJ proteins (27%), RF(56%), ACCP(50%),ANA(35%) and radiological investigations including chest X-ray (57%). Only (12%) received US scan of shoulders. There were wide differences in the treatment of PMR. Only 52(74%) of patients received initial management according to BSR guidelines. Rheumatologists did not prefer parenteral steroid injection as an initial management. Oral prednisolone dose reduction was compliant only in 29(41%) of patients. Although bone protection was considered in 64(90%) of patients, only 59(84%) followed the guidelines. Follow up of PMR patients were poorly compliant (43%). 33(47%) of patients experienced relapse, mostly within first 12 months. It highlighted wide variation in treatment of relapses e.g. incremental dose of prednisolone 31(45%) and DMARDs 11(16%). Patient education was provided with 68(96%) of our patients and 66(93%) received counselling from medical profession. Conclusion: We observed a wide variation in clinical practice in UK and it highlighted poor compliance to BSR guidelines in terms of diagnosis (64.3%), initiation (74%) and reduction (41%) of prednisolone dosage and follow-up of patients (43%). This reflects poor embedment of BSR guidelines among health professionals despite being in existence for last 3 years. Possible causes could be lack of awareness about existing guidelines, involvement of various disciplines (other than rheumatology) in management of PMR patients. We aspire to better adherence and implementation of national guidance across various specialities in order to provide best practice. Disclosure statement: The authors have declared no conflicts of interest. Background: Glucocorticoids (GCs) continue to be integral in the treatment of several rheumatic conditions and concerns over adverse effects (AEs) from prolonged GC exposure are certainly at the forefront of physician's and patient's minds. There is a deficiency in studies clarifying prevalence rates of the various AEs, particularly ones which do not lead to hospitalization or require specific treatment. To establish a consensus on monitoring practices, EULAR published recommendations in 2010 for the monitoring of AEs to be used in daily practice. Our group conducted a survey to assess prevalence rates of AEs associated with GCs and audited monitoring practice according to EULAR recommendations. Methods: Our study was conducted in the rheumatology department of the Cardiff & Vale University Health Board, between May and June 2013. Patients included were those who had been on GCs for >3 months. Assessment of monitoring compliance (measurements of blood pressure, fasting glucose, weight & height (to calculate BMI), bone densitometry) and occurrence of AEs was made through a combination of a pre-outpatient appointment interview and perusal of patient records. Appropriate monitoring was defined as patients who were assessed for all EULAR parameters. Additionally, we assessed patient's perceptions of how well they felt AEs were explained to them prior to commencing treatment. Results: Information was collected on 134 patients; mean prednisolone dose 9 mg daily. The most common AEs reported were weight gain (68.7%), ankle oedema (35.8%) and osteoporosis (20.9%). Several also reported eye problems including cataracts and glaucoma (16.4%). Aside from weight gain, over 40% had 1 additional cardiovascular risk factor. Only 4.5% of patients were appropriately monitored according to EULAR recommendations and 5.2% had no monitoring at all. About 50% of patients had timely densitometry assessments. The poorly measured parameters were mainly blood glucose at 27.6% and heights 32%. Two thirds of patients had regular blood pressure checks. Majority of patients (59%) felt GC related AEs were explained to them prior to treatment commencement. Only approximately a third recollected being provided a steroid information leaflet. Conclusion: Weight gain, cardiovascular risk and osteoporosis were the most prevalent AEs reported which likely reflects the rationale behind the EULAR monitoring recommendations. Compliance with EULAR recommendations for monitoring these key AEs was inconsistent and somewhat haphazard. The clearest pitfall was blood glucose monitoring. To ensure consistency in practice, we suggested a protocol to be developed, mirroring the EULAR recommendations, to be kept in all outpatient rooms as a prompter for clinicians. There is also a clear need for better communication with primary care to promote monitoring practices. Patients are expecting better dissemination of knowledge regarding the drugs they are prescribed; aside from the obligation of physicians to ensure this, better provision of information leaflets and online resources are vital. Disclosure statement: The authors have declared no conflicts of interest. Background: Clinical decisions are often complex, context-dependent and should be based where possible on best practice and individual patient needs. Shared decision making is an emerging strategy focussed on strengthening the collaboration between clinician and patient, by encouraging dialogue and discussion. JIA is the commonest inflammatory arthritis affecting children and young people (YP), continuing into adult life in 30% of patients. Over the past decade the treatment and management has changed significantly, including the emergence of multiple biologic therapies with their potential potency. There is a clear need for YP to be involved decisions about their own health management but this may require skills in both the CYP and healthcare professionals involved. This abstract outlines a project to empower YP. Methods: In a dedicated adolescent clinic, YP (12-18 years) attend medical review with consultant paediatric rheumatologists, facilitated by paediatric rheumatology specialist nurse (CNS). It was recognized that often parents made decisions about treatments with the YP opting out or having a passive role in decision-making. The department undertook a number of initiatives to improve this situation including: (i) optimization of the CNS role; (ii) audit of YP views of the service; (iii) development of strategies to improve YP involvement.
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Results: All YP attending the adolescent clinic are now seen by the CNS and encouraged to discuss their condition, treatment and other issues of concern. The view of YP were grouped into 15 themes and further developed into key questions regarding specific aspects of their health and wider generic adolescent health issues. YP were encouraged to take these questions into their medial consultations and formed the foundation for discussion and dialogue between the consultant and the YP. A variety of visual prompts in the waiting room were also used to stimulate further discussion and included question of the month, a topical newsletter and ask 3 things about your medicine postcards. Changes to the clinic are clear. The YP attends mainly unaccompanied and is actively engaged in the consultation. Generic health concerns are routinely addressed alongside review of their JIA and medication with greater involvement of the YP in decision making. Consultations have become more structured and focused and subsequently the clinic capacity has increased from 12 to 16 clinic appointments.
Conclusion:
The coaching role of the CNS is essential in the process to move a YP from a passive to active role in their consultation with the paediatric rheumatologist. The implementation of initiatives to improve i110 Downloaded from https://academic.oup.com/rheumatology/article-abstract/53/suppl_1/i110/1795632 by guest on 09 January 2019
